Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet
Phase 3
Recruiting
- Conditions
- Minor Traumatic Brain InjuryTreatment by Antiplatelet
- Interventions
- Biological: S100B protein dosing
- Registration Number
- NCT03780062
- Lead Sponsor
- Poitiers University Hospital
- Brief Summary
All the patients admitted in emergency department for minor traumatized cranial, with antiplatelet therapy, can be included, after checked inclusion and non inclusions criterias. If they are agree, a blood sample for the dosage of S100b will be done.
No other modification of the medical care, all patients will have tomodensitometria, according with recommendations. The aim of the study is to validate the negative predictive value of S100b in this population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 720
Inclusion Criteria
- Age > 18 Years old
- Minor traumatic brain injury measured by a Glasgow score between 13 and 15
- Antiplatelet agent therapy
- Free subject without tutorship or curatorship
Exclusion Criteria
- Age < 18 years old
- Glasgow score <13
- Traumatic brain injury older than 6 hours
- Patient without any social security system
- Patient with renforced protection (tutorship, curatorship, ...)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description S100B protein dosing S100B protein dosing -
- Primary Outcome Measures
Name Time Method Brain scanner Detection of a cerebral lesion requiring a surgery or medical intervention or an hospitalisation for a patient who have serum level of S100B protein with the treshold of 0.105 μg/L 3 hours
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
CHU of MONTPELLIER
🇫🇷Montpellier, France
CHU of NICE
🇫🇷Nice, France
La Pité Salpêtrière
🇫🇷Paris, France
CHU of POITIERS
🇫🇷Poitiers, France